Table 2.

The percent positive of the triage tests/methods for increasing severity of diagnosis among HPV DNA positives by sampling method (clinician or self) and test (careHPV™ or HC2)

careHPV+ (clinician)							HC2+ (clinician)
			HPV16/18/45							HPV16/18/45
	n	careHPV (≥10)	DNA2	E6	Colpo Impression	VIA (2nd)		n	HC2 (≥10)	E6	Colpo Impression	VIA (2nd)
Negative1	770	47.4	21.3	4.9	11.2	10.0	Negative1	771	52.9	4.9	12.2	11.0
CIN1	157	85.4	27.4	9.6	31.2	26.0	CIN1	167	83.8	9.6	32.3	27.5
CIN2	42	88.1	50.0	16.7	38.1	33.3	CIN2	42	90.5	16.7	38.1	33.3
CIN3	83	91.6	74.7	49.4	60.2	50.7	CIN3	83	91.6	49.4	60.2	50.7
Cancer	13	69.2	92.3	84.6	84.6	71.4	Cancer	13	84.6	84.6	84.6	71.4
CIN2+	138	88.4	68.8	42.8	55.8	46.1	CIN2+	138	90.6	42.8	55.8	46.1
CIN3+	96	88.5	77.1	54.2	63.5	52.6	CIN3+	96	90.6	54.2	63.5	52.6
careHPV + (self)							HC2+ (self)
			HPV16/18/45							HPV16/18/45
	n	careHPV (≥10)	DNA2	E6	Colpo Impression	VIA (2nd)		n	HC2 (≥10)	E6	Colpo Impression	VIA (2nd)
Negative1	811	42.7	16.9	3.1	9.5	8.7	Negative1	1033	46.5	3.1	10.4	9.3
CIN1	144	72.9	22.9	9.0	33.3	27.7	CIN1	164	73.8	9.2	36.0	30.8
CIN2	36	58.3	47.2	19.4	36.1	30.3	CIN2	42	69.1	19.1	38.1	33.3
CIN3	72	50.0	73.6	52.8	59.7	50.8	CIN3	79	69.6	50.6	59.5	51.5
Cancer	11	72.7	100.0	90.9	90.9	83.3	Cancer	11	72.7	90.9	90.9	83.3
CIN2+	119	54.6	68.1	46.2	55.5	46.0	CIN2+	132	69.7	43.9	55.3	46.9
CIN3+	83	53.0	77.1	57.8	63.9	53.7	CIN3+	90	70.0	55.6	63.3	54.2

¹Includes women who did not have biopsies and biopsies that were diagnosed as negative.

²careHPV™ test.

Abbreviations: CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2, CIN grade 2; CIN3, CIN grade 3, CIN2+, CIN2 or more severe; CIN3+, CIN3 or more severe; VIA, visual inspection with acetic acid; rlu/pc, relative light units per positive control (signal strength).